The global central nervous system biomarkers market size was estimated to be USD 5.18 billion in 2023 and is expected to reach USD 11.75 billion by 2034 with a CAGR of 7.73% during the forecast period 2024-2034. The market will rise as a result of the following factors: rising collaborations and partnerships, growing emphasis on early disease diagnosis, increasing investment in research and development, increasing incidence of neurological disorders, and advancements in biomarker discovery technologies.
Aging populations, shifting lifestyles, and environmental factors are all contributing to the sharp rise in the occurrence of neurological illnesses such as Parkinson's disease, multiple sclerosis, stroke, and Alzheimer's. Better diagnostic and treatment tools are therefore highly demanded, and biomarkers are essential to these efforts. For instance, Thermo Fisher Scientific introduced the Luminex LX 200 instrument in December 2023. This multiplex platform offers improved sensitivity and throughput for biomarker research.
By biomarker type, the efficacy biomarkers segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the advancements in precision medicine, increased focus on personalized treatment approaches, and the growing demand for biomarkers that provide insights into treatment responses and outcomes for neurological disorders. For instance, QIAGEN N.V. and Lundbeck collaborated in November 2023 to develop companion diagnostics for individualized therapy of depression. Additionally, the validation biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing importance of establishing robust and reliable biomarkers for regulatory approval processes, an increasing emphasis on ensuring the accuracy and reproducibility of diagnostic tools, and the rising adoption of standardized validation procedures across the pharmaceutical and diagnostic industries.
By application, the drug discovery and development segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the surge in research and development activities, a heightened focus on identifying novel therapeutic targets for central nervous system disorders, and the integral role played by biomarkers in streamlining drug discovery processes. For instance, Bio-Rad Laboratories, Inc. introduced the QIAcube Connect, a completely automated nucleic acid purification system, on October 26, 2023, which streamlined the workflows involved in biomarker research. Additionally, the personalized medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the unique genetic and molecular characteristics of individuals, increasing demand for targeted and customized treatment strategies, and advancements in genomics and molecular diagnostics.
By end-user, the clinics/hospitals segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the expanding need for accurate diagnostic tools in clinical settings, the rising incidence of central nervous system disorders, and the pivotal role of biomarkers in facilitating early diagnosis and treatment decisions. For instance, in September 2023, Siemens Healthineers AG and Pfizer worked together to discover and evaluate biomarkers for clinical studies pertaining to Parkinson's disease. Additionally, the research centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on innovative biomarker discovery, collaborative research initiatives, and the pivotal role of research centers in advancing scientific understanding of central nervous system disorders.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a robust presence of pharmaceutical and biotechnology companies engaged in CNS biomarker research and development, and the high prevalence of neurological disorders in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of neurological disorders, rising healthcare expenditure, a growing patient population, and expanding initiatives in biomarker research and development. For instance, Quanterix Corporation and Bio-Techne announced a strategic agreement in January 2024 to increase access to Simoa single-molecule array technology for biomarker identification.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Aging populations, shifting lifestyles, and environmental factors are all contributing to the sharp rise in the occurrence of neurological illnesses such as Parkinson's disease, multiple sclerosis, stroke, and Alzheimer's. Better diagnostic and treatment tools are therefore highly demanded, and biomarkers are essential to these efforts. For instance, Thermo Fisher Scientific introduced the Luminex LX 200 instrument in December 2023. This multiplex platform offers improved sensitivity and throughput for biomarker research.
By biomarker type, the efficacy biomarkers segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the advancements in precision medicine, increased focus on personalized treatment approaches, and the growing demand for biomarkers that provide insights into treatment responses and outcomes for neurological disorders. For instance, QIAGEN N.V. and Lundbeck collaborated in November 2023 to develop companion diagnostics for individualized therapy of depression. Additionally, the validation biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing importance of establishing robust and reliable biomarkers for regulatory approval processes, an increasing emphasis on ensuring the accuracy and reproducibility of diagnostic tools, and the rising adoption of standardized validation procedures across the pharmaceutical and diagnostic industries.
By application, the drug discovery and development segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the surge in research and development activities, a heightened focus on identifying novel therapeutic targets for central nervous system disorders, and the integral role played by biomarkers in streamlining drug discovery processes. For instance, Bio-Rad Laboratories, Inc. introduced the QIAcube Connect, a completely automated nucleic acid purification system, on October 26, 2023, which streamlined the workflows involved in biomarker research. Additionally, the personalized medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the unique genetic and molecular characteristics of individuals, increasing demand for targeted and customized treatment strategies, and advancements in genomics and molecular diagnostics.
By end-user, the clinics/hospitals segment accounted for the highest revenue-grossing segment in the global central nervous system biomarkers market in 2023 owing to the expanding need for accurate diagnostic tools in clinical settings, the rising incidence of central nervous system disorders, and the pivotal role of biomarkers in facilitating early diagnosis and treatment decisions. For instance, in September 2023, Siemens Healthineers AG and Pfizer worked together to discover and evaluate biomarkers for clinical studies pertaining to Parkinson's disease. Additionally, the research centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on innovative biomarker discovery, collaborative research initiatives, and the pivotal role of research centers in advancing scientific understanding of central nervous system disorders.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a robust presence of pharmaceutical and biotechnology companies engaged in CNS biomarker research and development, and the high prevalence of neurological disorders in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of neurological disorders, rising healthcare expenditure, a growing patient population, and expanding initiatives in biomarker research and development. For instance, Quanterix Corporation and Bio-Techne announced a strategic agreement in January 2024 to increase access to Simoa single-molecule array technology for biomarker identification.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Biomarker Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Central Nervous System Biomarkers Market Report 2023 - 2034
Central Nervous System Biomarkers Market Analysis & Forecast by Biomarker Type 2023 - 2034 (Revenue USD Bn)
- Safety Biomarkers
- Efficacy Biomarkers
- Validation Biomarkers
- Other Biomarkers
Central Nervous System Biomarkers Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery and Development
- Personalized Medicine
- Other Applications
Central Nervous System Biomarkers Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Diagnostic Labs
- Clinics/Hospitals
- Research Centers
Central Nervous System Biomarkers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Central Nervous System Biomarkers Market: Biomarker Type Estimates & Trend Analysis
8. Central Nervous System Biomarkers Market: Application Estimates & Trend Analysis
9. Central Nervous System Biomarkers Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Central Nervous System Biomarkers Market
12. Europe Global Central Nervous System Biomarkers Market
13. Asia Pacific Global Central Nervous System Biomarkers Market
14. Latin America Global Central Nervous System Biomarkers Market
15. MEA Global Central Nervous System Biomarkers Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers AG
- Quanterix Corporation
- Myriad RBM Inc.
- Merck KGaA (EMD Millipore)
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies Inc.
- Johnson & Johnson
- Abcam plc
- Athena Diagnostics Inc. (Quest Diagnostics)
- Cisbio Bioassays
- Aushon BioSystems (Quanterix Corporation)
- PerkinElmer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.18 Billion |
| Forecasted Market Value ( USD | $ 11.75 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
